Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
Wenhua Liang(First Affiliated Hospital of Guangzhou Medical University), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Wensen Chen(Johnson & Johnson (United States)), Gening Jiang(Tongji University), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Qian Zhou(Anhui Medical University), Calvin S.H. Ng(Johnson & Johnson (United States)), René Horsleben Petersen(Johnson & Johnson (United States)), Deruo Liu(Roswell Park Comprehensive Cancer Center), Yaxing Shen(Johnson & Johnson (United States)), Jiaxi He(Johnson & Johnson (United States)), Lunxu Liu(Sichuan University), Jianrong Zhang(Fudan University), Alessandro Brunelli(St James's University Hospital), Qun Wang(Sun Yat-sen University), Zheng Wang(Shanghai Jiao Tong University), Bo Liu(Jilin University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Jianfei Shen(Wenzhou Medical University), Thomas A. D’Amico(General Marble (Greece)), Yixin Yang(Chinese Academy of Sciences), Chia-Chuan Liu(National Cheng Kung University), Qihua He(Peking University), Zhihua Zhu(Johnson & Johnson (United States)), Haiquan Chen(Shanghai Jiao Tong University), Gaetano Rocco(Memorial Sloan Kettering Cancer Center)
Cited by 358
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k